Abstract
Limited efficacy of current therapeutic approaches for neurodegenerative disease has led to increased interest in alternative therapies. Cord blood plasma (CBP) derived from human umbilical cord blood (hUCB) may be a potential therapeutic. Benefits of CBP injection into rodent models of aging or ischaemic stroke have been demonstrated, though how benefits are elicited is still unclear. The present study evaluated various factors within the same samples of CBP and human adult blood plasma/sera (ABP/S). Also, autologous CBP effects vs. ABP/S or foetal bovine serum supplements on mononuclear cells from hUCB (MNC hUCB) in vitro were determined. Results showed significantly low concentrations of pro‐inflammatory cytokines (IL‐2, IL‐6, IFN‐γ, and TNF‐α) and elevated chemokine IL‐8 in CBP. Significantly higher levels of VEGF, G‐CSF, EGF and FGF‐basic growth factors were determined in CBP vs. ABP/S. Autologous CBP media supplements significantly increased MNC hUCB viability and decreased apoptotic cell activity. We are first to demonstrate the unique CBP composition of cytokines and growth factors within the same CBP samples derived from hUCB. Also, our novel finding that autologous CBP promoted MNC hUCB viability and reduced apoptotic cell death in vitro supports CBP's potential as a sole therapeutic or cell‐additive agent in developing therapies for various neurodegenerative diseases.
Highlights
Cord blood plasma (CBP) is commonly obtained from human umbilical cord blood during cell isolation and has mainly been considered a waste product
Apoptotic activity of cultured mononuclear cells (MNC) human umbilical cord blood (hUCB) in media supplemented with autologous CBP, adult blood plasma/sera (ABP/S), or foetal bovine serum (FBS) was analyzed on day 5 in vitro using a colormetric TUNEL assay
Various factors in CBP derived from hUCB and the effect of CBP on mononuclear cells isolated from hUCB (MNC hUCB) in vitro were evaluated in the context of establishing CBP as a potential therapeutic agent
Summary
Cord blood plasma (CBP) is commonly obtained from human umbilical cord blood (hUCB) during cell isolation and has mainly been considered a waste product. The therapeutic potential of CBP administration into rats modelling acute ischaemic stroke was demonstrated by enhancement of neurogenesis and reduction of inflammation leading to significant post‐stroke functional recovery.[5] tissue inhibitor of metalloproteinases 2, a plasticity‐enhancing protein from CBP, has been found to promote restoration of hippocampal function and memory in aged 18 months old mice after CBP treatment.[6] A recent study[7] showed beneficial functional improvement in an. These study results provide a basis for further establishment of CBP as a potential self‐contained therapeutic or as a supportive diluent for MNC hUCB infusion in treatment of neurodegenerative diseases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
